These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 14761911)
1. Is there a role for isolated limb perfusion with tumor necrosis factor in patients with melanoma? De Wilt JH; Thompson JF Ann Surg Oncol; 2004 Feb; 11(2):119-21. PubMed ID: 14761911 [No Abstract] [Full Text] [Related]
2. Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. Deroose JP; Eggermont AM; van Geel AN; Verhoef C Curr Opin Oncol; 2011 Mar; 23(2):183-8. PubMed ID: 21150602 [TBL] [Abstract][Full Text] [Related]
3. Regional treatment of metastasis: role of regional perfusion. State of the art isolated limb perfusion for limb salvage. Eggermont AM; Brunstein F; Grünhagen D; ten Hagen TL Ann Oncol; 2004; 15 Suppl 4():iv107-12. PubMed ID: 15477292 [No Abstract] [Full Text] [Related]
4. Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion. Testori A; Verhoef C; Kroon HM; Pennacchioli E; Faries MB; Eggermont AM; Thompson JF J Surg Oncol; 2011 Sep; 104(4):397-404. PubMed ID: 21858835 [TBL] [Abstract][Full Text] [Related]
5. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Rossi CR; Foletto M; Mocellin S; Pilati P; Lise M Ann Surg Oncol; 2004 Feb; 11(2):173-7. PubMed ID: 14761920 [TBL] [Abstract][Full Text] [Related]
7. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan. Vaglini M; Santinami M; Manzi R; Inglese MG; Santoro N; Persiani L; Belli F Melanoma Res; 1994 Mar; 4 Suppl 1():35-8. PubMed ID: 8038594 [TBL] [Abstract][Full Text] [Related]
8. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330 [TBL] [Abstract][Full Text] [Related]
9. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Zogakis TG; Bartlett DL; Libutti SK; Liewehr DJ; Steinberg SM; Fraker DL; Alexander HR Ann Surg Oncol; 2001 Dec; 8(10):771-8. PubMed ID: 11776490 [TBL] [Abstract][Full Text] [Related]
10. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234 [TBL] [Abstract][Full Text] [Related]
11. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma]. Kettelhack C; Hohenberger P; Schlag PM Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487 [TBL] [Abstract][Full Text] [Related]